Fasudil hydrochloride
Code | Size | Price |
---|
TAR-T3060-50mg | 50mg | £99.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3060-100mg | 100mg | £107.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3060-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3060-200mg | 200mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3060-500mg | 500mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Fasudil Hydrochloride is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
CAS:
105628-07-7
Formula:
C14H18ClN3O2S
Molecular Weight:
327.83
Pathway:
Metabolism; Microbiology/Virology; Autophagy; Tyrosine Kinase/Adaptors; Membrane transporter/Ion channel; Chromatin/Epigenetic; Cytoskeletal Signaling; Proteases/Proteasome; Stem Cells; Cell Cycle/Checkpoint
Purity:
0.9998
SMILES:
Cl.O=S(=O)(N1CCCNCC1)c1cccc2cnccc12
Target:
ROCK; Serine/threonin kinase; Calcium Channel; HIV Protease; PKA; PKC; Autophagy
References
1. Ono-Saito N, et al. Pharmacol Ther, 1999, 82(2-3), 123-131.
2. Asano T, et al. J Pharmacol Exp Ther, 1987, 241(3), 1033-1040.
3. Asano T, et al. Br J Pharmacol, 1989, 98(4), 1091-1100.
4. Negoro N, et al. Biochem Biophys Res Commun, 1999, 262(1), 211-215.
5. Fukushima M, et al. Liver Int, 2005, 25(4), 829-838.